fenofibrate has been researched along with Necrosis in 5 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 7.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | 5.42 | Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 3.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | 1.42 | Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 3 |
| Yang, S | 3 |
| Liu, L | 3 |
| Yang, X | 3 |
| Duan, Y | 3 |
| Zhang, S | 3 |
| Han, J | 3 |
| Li, P | 1 |
| Luo, S | 1 |
| Pan, C | 1 |
| Cheng, X | 1 |
| Okada, M | 1 |
| Sano, F | 1 |
| Ikeda, I | 1 |
| Sugimoto, J | 1 |
| Takagi, S | 1 |
| Sakai, H | 1 |
| Yanai, T | 1 |
| Steinhoff, M | 1 |
| Beyer, M | 1 |
| Roewert-Huber, J | 1 |
| Lukowsky, A | 1 |
| Assaf, C | 1 |
| Sterry, W | 1 |
| Berger, O | 1 |
| Zifko, U | 1 |
| Jellinger, K | 1 |
| Machacek, E | 1 |
| Grisold, W | 1 |
1 review available for fenofibrate and Necrosis
| Article | Year |
|---|---|
[Necrotizing myopathy with antilipemic agents. Case report and review of the literature].
Topics: Aged; Biopsy; Creatine Kinase; Electromyography; Fenofibrate; Humans; Hyperlipidemias; Long-Term Car | 1993 |
4 other studies available for fenofibrate and Necrosis
| Article | Year |
|---|---|
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate.
Topics: Animals; Cells, Cultured; Energy Metabolism; Fatty Acids; Fenofibrate; Heart Failure; Hypolipidemic | 2015 |
Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats.
Topics: Animals; Data Interpretation, Statistical; Fenofibrate; Fibrosis; Gene Expression; Gene Expression P | 2009 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fev | 2008 |